{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:25:26Z","timestamp":1778678726876,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The purpose of this study was to evaluate the post-marketing safety and effectiveness of aripiprazole in treating irritability in pediatric patients (6\u201317\u2009years) with autism spectrum disorder (ASD) in actual clinical sites of Japan.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this post-marketing surveillance, patients were enrolled into the multicenter, prospective, non-interventional, observational study for 52\u2009weeks, and were dosed with aripiprazole (1\u201315\u2009mg\/day) under daily clinical settings in Japan.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In 510 patients, the continuation rate of aripiprazole treatment was 84.6% at day 168 (week 24) and 78.1% at day 364 (week 52). Adverse drug reactions (ADRs) occurred in 22.7% of patients (<jats:italic>n<\/jats:italic>\u2009=\u2009116), and the most common ADRs were somnolence (9.4%), followed by weight increased (3.3%). At week 4, the mean change from baseline in the irritability subscale score for the Aberrant Behavior Checklist Japanese version (ABC-J) was \u2212\u20095.7\u2009\u00b1\u20096.8 (<jats:italic>n<\/jats:italic>\u2009=\u2009288). Based on multiple regression analysis, comorbid attention deficit and hyperactivity did not affect the ABC-J irritability subscale score at endpoint. At week 24, the mean change from baseline for the Strengths and Difficulties Questionnaire was \u2212\u20093.3\u2009\u00b1\u20094.9 (<jats:italic>n<\/jats:italic>\u2009=\u2009215) for the total difficulties score and 0.6\u2009\u00b1\u20091.7 (<jats:italic>n<\/jats:italic>\u2009=\u2009217) for the prosocial behavior subscale score.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Aripiprazole was well tolerated and effective in the long-term treatment of irritability associated with ASD in Japanese pediatric patients in the real-world clinical practice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>This surveillance was registered with Clinical Trial.gov (no. <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/\">NCT03179787<\/jats:ext-link>) on June 7, 2017 (retrospectively registered).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-021-03201-6","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T11:08:28Z","timestamp":1619089708000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Aripiprazole in the real-world treatment for irritability associated with autism spectrum disorder in children and adolescents in Japan: 52-week post-marketing surveillance"],"prefix":"10.1186","volume":"21","author":[{"given":"Yuna","family":"Sugimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayo","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyo","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Fukuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsunaka","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akemi","family":"Tomoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,22]]},"reference":[{"key":"3201_CR1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, 5th edn","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edn. Arlington, VA: American Psychiatric Publishing; 2013."},{"issue":"12","key":"3201_CR2","doi-asserted-by":"publisher","first-page":"32S","DOI":"10.1016\/S0890-8567(99)80003-3","volume":"38","author":"F Volkmar","year":"1999","unstructured":"Volkmar F, Cook EH, Pomeroy J, Realmuto G, Tanguay P. Practice parameters for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders. American Academy of Child and Adolescent Psychiatry working group on quality issues. J Am Acad Child Adolesc Psychiatry. 1999;38(12):32S\u201354S. https:\/\/doi.org\/10.1016\/S0890-8567(99)80003-3.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"3201_CR3","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1542\/peds.2007-2362","volume":"120","author":"SM Myers","year":"2007","unstructured":"Myers SM, Johnson CP. American Academy of Pediatrics Council on children with disabilities. Management of children with autism spectrum disorders. Pediatrics. 2007;120(5):1162\u201382. https:\/\/doi.org\/10.1542\/peds.2007-2362.","journal-title":"Pediatrics."},{"issue":"2-3","key":"3201_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ejphar.2007.07.031","volume":"574","author":"Y Tadori","year":"2007","unstructured":"Tadori Y, Kitagawa H, Forbes RA, McQuade RD, Stark A, Kikuchi T. Differences in agonist\/antagonist properties at human dopamine D2 receptors between aripiprazole, bifeprunox and SDZ 208-912. Eur J Pharmacol. 2007;574(2-3):103\u201311. https:\/\/doi.org\/10.1016\/j.ejphar.2007.07.031.","journal-title":"Eur J Pharmacol"},{"key":"3201_CR5","doi-asserted-by":"publisher","unstructured":"Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan T, et al. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor binding and in vivo electrophysiological studies. Psychopharmacology. 2007;190(3):373\u201382. https:\/\/doi.org\/10.1007\/s00213-006-0621-y.","DOI":"10.1007\/s00213-006-0621-y"},{"key":"3201_CR6","unstructured":"Otsuka America Pharmaceutical, Inc. Aripiprazole [package insert]. Rockville; 2020. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/safetylabelingchanges\/."},{"key":"3201_CR7","unstructured":"Otsuka Pharmaceutical Netherlands B.V. Aripiprazole [summary of product characteristics]. Amsterdam; 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/abilify."},{"issue":"3","key":"3201_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40272-013-0024-6","volume":"15","author":"S Caccia","year":"2013","unstructured":"Caccia S. Safety and pharmacokinetics of atypical antipsychotics in children and adolescents. Pediatr Drugs. 2013;15(3):217\u201333. https:\/\/doi.org\/10.1007\/s40272-013-0024-6.","journal-title":"Pediatr Drugs"},{"key":"3201_CR9","doi-asserted-by":"publisher","unstructured":"Ichikawa H, Mikami K, Okada T, Yamashita Y, Ishizaki Y, Tomoda A, et al. Aripiprazole in the treatment of irritability in children and adolescents with autism spectrum disorder in Japan: a randomized, double-blind, placebo-controlled study. Child Psychiat Hum D. 2017;48(5):796\u2013806. https:\/\/doi.org\/10.1007\/s10578-016-0704-x.","DOI":"10.1007\/s10578-016-0704-x"},{"key":"3201_CR10","first-page":"1481","volume":"19","author":"H Ichikawa","year":"2016","unstructured":"Ichikawa H, Hiratani M, Yasuhara A, et al. An open-label extension study of the safety and efficacy of aripiprazole for irritability in children and adolescents with autistic disorder: an interim report. Jpn J Clin Psychopharmacol. 2016;19:1481\u201392 (in Japanese).","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"3201_CR11","doi-asserted-by":"publisher","unstructured":"Ichikawa H, Hiratani M, Yasuhara A, Tsujii N, Oshimo T, Ono H, et al. An open-label extension long-term study of the safety and efficacy of aripiprazole for irritability in children and adolescents with autistic disorder in Japan. Psychiatry Clin Neurosci. 2018;72(2):84\u201394. https:\/\/doi.org\/10.1111\/pcn.12607.","DOI":"10.1111\/pcn.12607"},{"key":"3201_CR12","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, 4th edn, text revision edn","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn, text revision edn. Washington, DC: American Psychiatric Association; 2000."},{"issue":"6","key":"3201_CR13","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1542\/peds.2008-3782","volume":"124","author":"R Owen","year":"2009","unstructured":"Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124(6):1533\u201340. https:\/\/doi.org\/10.1542\/peds.2008-3782.","journal-title":"Pediatrics."},{"key":"3201_CR14","doi-asserted-by":"publisher","unstructured":"Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(11):1110\u20139. https:\/\/doi.org\/10.1097\/CHI.0b013e3181b76658.","DOI":"10.1097\/CHI.0b013e3181b76658"},{"issue":"09","key":"3201_CR15","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.4088\/JCP.09m05933","volume":"72","author":"RN Marcus","year":"2011","unstructured":"Marcus RN, Owen R, Manos G, Mankoski R, Kamen L, McQuade RD, et al. Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, openlabel, multicenter study. J Clin Psychiatry. 2011;72(09):1270\u20136. https:\/\/doi.org\/10.4088\/JCP.09m05933.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"3201_CR16","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1089\/cap.2009.0121","volume":"21","author":"RN Marcus","year":"2011","unstructured":"Marcus RN, Owen R, Manos G, Mankoski R, Kamen L, McQuade RD, et al. Aripiprazole in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder: results from a 52-week, open-label study. J Child Adolesc Psychopharmacol. 2011;21(3):229\u201336. https:\/\/doi.org\/10.1089\/cap.2009.0121.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"3201_CR17","unstructured":"Otsuka Pharmaceutical Co., Ltd. Aripiprazole [package insert]. Tokyo, Japan, Revised September 2020 (in Japanese)."},{"issue":"4","key":"3201_CR18","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/0891-4222(96)00015-7","volume":"17","author":"Y Ono","year":"1996","unstructured":"Ono Y. Factor validity and reliability for the aberrant behavior checklist-Community in a Japanese population with mental retardation. Res Dev Disabil. 1996;17(4):303\u20139. https:\/\/doi.org\/10.1016\/0891-4222(96)00015-7.","journal-title":"Res Dev Disabil"},{"issue":"5","key":"3201_CR19","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/j.1469-7610.1997.tb01545.x","volume":"38","author":"R Goodman","year":"1997","unstructured":"Goodman R. The strengths and difficulties questionnaire: a research note. J Child Psychol Psychiatry. 1997;38(5):581\u20136. https:\/\/doi.org\/10.1111\/j.1469-7610.1997.tb01545.x.","journal-title":"J Child Psychol Psychiatry"},{"key":"3201_CR20","doi-asserted-by":"publisher","unstructured":"Matsuishi T, Nagano M, Araki Y, Tanaka Y, Iwasaki M, Yamashita Y, et al. Scale properties of the Japanese version of the strengths and difficulties questionnaire (SDQ): a study of infant and school children in community samples. Brain and Development. 2008;30(6):410\u20135. https:\/\/doi.org\/10.1016\/j.braindev.2007.12.003.","DOI":"10.1016\/j.braindev.2007.12.003"},{"key":"3201_CR21","doi-asserted-by":"publisher","unstructured":"Hirshkowitz M, Whiton K, Albert SM, Alessi C, Bruni O, DonCarlos L, et al. National Sleep Foundation\u2019s sleep time duration recommendations: methodology and results summary. Sleep Health. 2015;1(1):40\u20133. https:\/\/doi.org\/10.1016\/j.sleh.2014.12.010.","DOI":"10.1016\/j.sleh.2014.12.010"},{"issue":"12","key":"3201_CR22","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s00127-010-0294-z","volume":"46","author":"G Russell","year":"2011","unstructured":"Russell G, Steer C. Golding J social and demographic factors that influence the diagnosis of autistic spectrum disorders. Soc Psychiatry Psychiatr Epidemiol. 2011;46(12):1283\u201393. https:\/\/doi.org\/10.1007\/s00127-010-0294-z.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"3201_CR23","doi-asserted-by":"publisher","unstructured":"Iizuka C, Yamashita Y, Nagamitsu S, Yamashita T, Araki Y, Ohya T, et al. Comparison of the strengths and difficulties questionnaire (SDQ) scores between children with high-functioning autism spectrum disorder (HFASD) and attention-deficit\/hyperactivity disorder (AD\/HD). Brain and Development. 2010;32(8):609\u201312. https:\/\/doi.org\/10.1016\/j.braindev.2009.09.009.","DOI":"10.1016\/j.braindev.2009.09.009"},{"key":"3201_CR24","doi-asserted-by":"publisher","unstructured":"Robb AS, Andersson C, Bellocchio EE, Manos G, Rojas-Fernandez C, Mathew S, et al. Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6-17 years old):results from a pooled analysis of 2 studies. Prim Care Companion CNS Disord. 2011;13(1):1\u20139. https:\/\/doi.org\/10.4088\/PCC.10m01008gry.","DOI":"10.4088\/PCC.10m01008gry"},{"key":"3201_CR25","doi-asserted-by":"publisher","unstructured":"Mankoski R, Stockton G, Manos G, Marler S, McQuade R, Forbes RA, et al. Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. J Child Adolesc Psychopharmacol. 2013;23(8):572\u20136. https:\/\/doi.org\/10.1089\/cap.2012.0075.","DOI":"10.1089\/cap.2012.0075"},{"issue":"1","key":"3201_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1089\/cap.2020.0014","volume":"31","author":"N Coustals","year":"2021","unstructured":"Coustals N, Menard ML, Cohen D. Aripiprazole in children and adolescents. J Child Adolesc Psychopharmacol. 2021;31(1):4\u201332. https:\/\/doi.org\/10.1089\/cap.2020.0014.","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"3201_CR27","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.2147\/NDT.S174622","volume":"14","author":"N Maneeton","year":"2018","unstructured":"Maneeton N, Maneeton B, Putthisri S, Suttajit S, Likhitsathian S, Srisurapanont M. Aripiprazole in acute treatment of children and adolescents with autism spectrum disorder: a systematic review and metaanalysis. Neuropsychiatr Dis Treat. 2018;14:3063\u201372. https:\/\/doi.org\/10.2147\/NDT.S174622.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"3201_CR28","doi-asserted-by":"publisher","unstructured":"Hirsch LE, Pringsheim T. Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2016;(6). Art. No.: CD009043. https:\/\/doi.org\/10.1002\/14651858.CD009043.pub3.","DOI":"10.1002\/14651858.CD009043.pub3"},{"issue":"9920","key":"3201_CR29","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(13)61539-1","volume":"383","author":"MC Lai","year":"2014","unstructured":"Lai MC, Lombardo MV, Baron-Cohen S. Autism. Lancet. 2014;383(9920):896\u2013910. https:\/\/doi.org\/10.1016\/S0140-6736(13)61539-1.","journal-title":"Lancet."}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-021-03201-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-021-03201-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-021-03201-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T11:10:44Z","timestamp":1619089844000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-021-03201-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,22]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3201"],"URL":"https:\/\/doi.org\/10.1186\/s12888-021-03201-6","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,22]]},"assertion":[{"value":"25 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This surveillance was conducted in compliance with the Ministerial Ordinance on Standards for Conducting Post-marketing Surveys and Studies on Drugs; MHLW Ordinance No. 171 issued on December 20, 2004 (GPSP). As the surveillance is a non-interventional study in accordance with GPSP, the need for ethics approval and consent were waived. The surveillance was designed by Otsuka, reviewed by the Japanese Pharmaceutical and Medical Devices Agency (PMDA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study was funded by Otsuka Pharmaceutical Co., Ltd. KM and AT have received consulting fees from Otsuka Pharmaceutical Co., Ltd. based on contract. YS, KY, TT, YF and KA are employees of Otsuka Pharmaceutical Co., Ltd. KM has received: a) research support from Grant-in-Aid for Scientific Research (C) (Grant Number 18\u2009K07611), Taisho Pharmaceutical, Otsuka Pharmaceutical, Shionogi & Co., Japanese Society for Probiotic Science; b) honoraria from Otsuka Pharmaceutical, Shionogi & Co., Shire Japan, Eli Lilly and Co., Meiji Holdings Co., Takeda Pharmaceutical, MIYARISAN PHARMACEUTICAL CO; and c) a consulting fee from Shionogi & Co and Viatris.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"204"}}